secwatch.observer — SEC 8-K summary
======================================

Issuer:     TANDEM DIABETES CARE INC (TNDM)
CIK:        0001438133
Form:       8-K
Filed at:   2022-02-16T23:59:59+00:00
Accession:  0001438133-22-000014
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears Tandem Diabetes t:slim X2 insulin pump to deliver bolus via smartphone app
--------------------------------------------------------------------------------

- FDA cleared t:slim X2 insulin pump to program and cancel bolus insulin doses using t:connect mobile app on iOS and Android.
- First smartphone app to receive FDA clearance for insulin delivery on both operating systems.
- Feature will be available via remote software update at no extra cost to new and in-warranty customers.
- Rollout begins spring with limited launch groups, expanded launch expected later summer.
- CEO John Sheridan highlights this as one of most requested feature enhancements for Control-IQ technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438133/000143813322000014/0001438133-22-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438133/000143813322000014/tndm-20220216.htm
  HTML page:      https://secwatch.observer/filing/0001438133-22-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer